COPD. Chronic obstructive pulmonary disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Participants in the intervention group will receive verapamil 5 mg (equivalent to 2 mL of a 2.5 mg/mL solution) twice daily via nebulization over a period of 10 min
Sponsors
Sanandaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (Chronic bronchitis) Patients aged over 40 years Patients who are hospitalized due to disease exacerbation. Patients who provide informed written consent to participate in the study
Exclusion criteria
Exclusion criteria: Pregnancy Severe hepatic failure Severe renal failure Respiratory disorders other than COPD Cardiac arrhythmia Left ventricular ejection fraction (EF) less than 40% History of hypersensitivity to verapamil Bradycardia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dyspnea Severity. Timepoint: Measurement of dyspnea severity at baseline (before the start of the intervention) and five days after initiating verapamil administration. Method of measurement: Modified Borg Scale.;Oxygen Saturation. Timepoint: Measurement of oxygen saturation at baseline (before the start of the intervention) and five days after initiating verapamil administration. Method of measurement: Pulse Oximeter.;Pulmonary Artery Pressure. Timepoint: Measurement of pulmonary artery pressure at baseline (before the start of the intervention) and five days after initiating verapamil administration. Method of measurement: Echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Rezaei Abkenar
Sanandaj University of Medical Sciences
Outcome results
None listed